Brevetti Gregorio, Oliva Gabriella, Giugliano Giuseppe, Schiano Vittorio, De Maio Julieta Isabel, Chiariello Massimo
Department of Clinical Medicine and Cardiovascular and Immunological Sciences, University of Napoli Federico II, Naples, Italy.
J Gen Intern Med. 2007 May;22(5):639-44. doi: 10.1007/s11606-007-0162-z. Epub 2007 Mar 13.
Peripheral arterial disease (PAD) is undertreated by general practitioners (GPs). However, the impact of the suboptimal clinical management is unknown.
To assess the mortality rate of PAD patients in relation to the type of physician who provides their care (GP or vascular specialist).
Prospective study.
Primary care practice and academic vascular laboratory.
GP patients (n = 60) were those of the Peripheral Arteriopathy and Cardiovascular Events study (PACE). Patients managed by specialists (n = 82) were consecutive subjects with established PAD who were referred to our vascular laboratory during the enrollment period of the PACE study.
All-cause and cardiovascular mortality.
After 32 months of follow-up, specialist management was associated with a lower rate of all-cause mortality (RR = 0.04; 95% CI 0.01-0.34; p = .003) and cardiovascular mortality (RR = 0.07; 95% CI 0.01-0.65; p = .020), after adjustment for patients' characteristics. Specialists were more likely to use antiplatelet agents (93% vs 73%, p < .001), statins (62% vs 25%, p < .001) and beta blockers (28% vs 3%, p < .001). Survival differences between specialists and GPs disappeared once the use of pharmacotherapies was added to the proportional hazard model. The fully adjusted model showed that the use of statins was significantly associated with a reduced risk of all-cause mortality (RR = 0.02; 95% CI 0.01-0.73, p = .034) and cardiovascular mortality (RR = 0.02; 95% CI 0.01-0.71, p = .033).
Specialist management of patients with symptomatic PAD resulted in better survival than generalist management. This effect appears to be mainly caused by the more frequent use of effective medicines by specialists.
外周动脉疾病(PAD)在全科医生(GP)的治疗中未得到充分治疗。然而,次优临床管理的影响尚不清楚。
评估与提供治疗的医生类型(全科医生或血管专科医生)相关的PAD患者死亡率。
前瞻性研究。
初级保健机构和学术血管实验室。
全科医生患者(n = 60)来自外周动脉病与心血管事件研究(PACE)。由专科医生管理的患者(n = 82)是在PACE研究入组期间被转诊至我们血管实验室的已确诊PAD的连续病例。
全因死亡率和心血管死亡率。
经过32个月的随访,在对患者特征进行调整后,专科医生管理与较低的全因死亡率(RR = 0.04;95%CI 0.01 - 0.34;p = 0.003)和心血管死亡率(RR = 0.07;95%CI 0.01 - 0.65;p = 0.020)相关。专科医生更有可能使用抗血小板药物(93%对73%,p < 0.001)、他汀类药物(62%对25%,p < 0.001)和β受体阻滞剂(28%对3%,p < 0.001)。一旦将药物治疗的使用纳入比例风险模型,专科医生和全科医生之间的生存差异就消失了。完全调整后的模型显示,使用他汀类药物与降低全因死亡率(RR = 0.02;95%CI 0.01 - 0.73,p = 0.034)和心血管死亡率(RR = 0.02;95%CI 0.01 - 0.71,p = 0.033)的风险显著相关。
有症状PAD患者的专科医生管理比全科医生管理导致更好的生存。这种效果似乎主要是由专科医生更频繁地使用有效药物引起的。